Sharemaestro Newsreel

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

Apyx Medical Corporation reported its second-quarter 2026 financial results, with total revenue of $13.9 million, primarily driven by a 28% growth in its Surgical Aesthetics segment. The company reaffirmed its full-year 2026 revenue guidance of $59.0 million to $60.0 million and highlighted the successful …

Apyx Medical Reports Q2 2026 Revenue of $13.9M, Surgical Aesthetics Up 28%

Apyx Medical announced its Q2 2026 financial results, reporting total revenue of $13.9 million, a 22% year-over-year increase, largely driven by a 28% growth in its Surgical Aesthetics segment. Despite a GAAP net loss of $3.2 million and an adjusted EBITDA loss of $0.7 …

Apyx Medical’s AYON System Gains FDA 510(k) Clearance for Power Liposuction

Apyx Medical reported Q2 2026 revenue of $13.9 million, a 22% year-over-year increase, primarily driven by 28% growth in its Surgical Aesthetics segment. The company also announced expanded FDA 510(k) clearance for its AYON Body Contouring System to include power liposuction and reaffirmed its …

Lazard Asset Management LLC Buys New Holdings in Beta Bionics, Inc. $BBNX

Lazard Asset Management LLC has acquired a new stake of 71,905 shares in Beta Bionics (NASDAQ:BBNX), valued at approximately $720,000, representing 0.16% ownership. Other institutional investors also established or increased positions in the company. Beta Bionics shares recently traded down 4.5% at $13.91, with …

Delcath Systems (NASDAQ:DCTH) Price Target Raised to $21.00 at BTIG Research

BTIG Research has raised its price target for Delcath Systems (NASDAQ:DCTH) to $21.00 from $17.00, maintaining a "Buy" rating and implying a 40% upside. This follows Delcath's strong quarterly performance, where it exceeded revenue and EPS expectations. The stock surged 18.8% to $15.00 on …

Profound Medical (NASDAQ: PROF) boosts revenue 62% while cutting loss

Profound Medical Corp. (NASDAQ: PROF) announced a significant revenue increase of 62% for the six months ended June 30, 2026, reaching $7.82 million, primarily due to higher capital equipment sales and recurring non-capital revenue. The company also narrowed its net loss to $16.59 million …

About $3.1M of Profound shipments will count as Q3 revenue

Profound Medical (NASDAQ:PROF) reported Q2 2026 revenue of $2.5 million, an increase of 12% year-over-year. Approximately $3.1 million in TULSA shipments were delayed to July due to logistics, which would have increased Q2 revenue to $5.6 million, representing 153% growth. The company reiterated its …

CVRx (NASDAQ: CVRX) grows Q2 2026 revenue but cuts outlook

CVRx, Inc. reported a 16% increase in Q2 2026 revenue to $15.7 million, primarily driven by U.S. heart failure sales, with gross profit rising to $13.7 million and gross margin improving to 87%. Despite this growth, the company posted a net loss of $14.0 …

CVRx Reports Second Quarter 2026 Financial and Operating Results

CVRx, Inc. announced its Q2 2026 financial results, reporting $15.7 million in total revenue, a 16% increase year-over-year, and a gross margin of 87%. Despite strong growth and a new Medicare Advantage coverage policy from Humana for its Barostim therapy, the company updated its …

Earnings Preview: NeuroPace to Report Financial Results Post-market on August 11

This article announces that NeuroPace is scheduled to release its financial results after the market closes on August 11. Investors and analysts will be keen to review the company's performance and outlook during the upcoming earnings call.

Earnings call transcript: Enovis tops Q2 2026 EPS view but shares fall 6.7%

iRhythm Holdings Announces Second Quarter 2026 Financial Results

iRhythm SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2026. Second …

Hyperfine, Inc. Provides Earnings Guidance for the Full Year 2026

electroCore's Quell Sales Reach $1.3M, Up About 700%

AVITA Medical expects cash flow breakeven in fourth quarter 2026

Pomerantz Law Firm Announces the Filing of a Class Action Against Nano-X Imaging Ltd. and Certain Officers - NNOX

Pomerantz LLP has filed a class action lawsuit against Nano-X Imaging Ltd. (NASDAQ: NNOX) and certain officers, alleging materially false and misleading statements were made to investors between March 31, 2025, and April 17, 2026. The lawsuit claims Nano-X overstated efficiency gains and demand, …

UBS Group Forecasts Strong Price Appreciation for Sight Sciences (NASDAQ:SGHT) Stock

AdaptHealth (AHCO) Stock Faces Deeper Doubts After Profit Reset

Canaccord raises Establishment Labs stock price target on strong US growth

Integer Holdings (ITGR) Stock Margins Improve As Debt Questions Persist

Pulsenmore (PLSM) investors back six proposals at 2026 AGM

Pulsenmore Ltd. (PLSM) announced that its shareholders approved all six proposals presented at the 2026 Annual General Meeting held on August 6, 2026. These proposals were previously detailed in the Notice of Annual General Meeting dated July 1, 2026, which was furnished to the …

IceCure Medical (ICCM) holders approve agenda after adjourned meeting

IceCure Medical Ltd. shareholders approved the agenda item during a Special General Meeting held on August 6, 2026. The meeting was initially adjourned due to a lack of quorum but reconvened later the same day once sufficient shareholder presence was achieved. This information was …

Hyperfine (Nasdaq: HYPR) grows Q2 2026 revenue 44.8% as cash rises to $43.5M

Hyperfine, Inc. reported a significant 44.8% increase in Q2 2026 revenue, reaching $3.9 million, with cash and cash equivalents growing to $43.5 million. The company also announced CE Mark and UKCA approvals and the European launch of its next-generation Swoop® portable MRI system, alongside …

Why Enovis (ENOV) Shares Are Sliding Today

Enovis Corporation's shares fell 12.8% after reporting second-quarter earnings, despite revenue and adjusted earnings surpassing Wall Street expectations. The decline was attributed to a weaker full-year earnings per share outlook and a significant contraction in the company's adjusted operating margin, which fell 6.7 percentage …

Artivion Reports Second Quarter 2026 Financial Results

Artivion, Inc. announced strong financial results for the second quarter of 2026, with revenue increasing 11% on a GAAP basis and 9% on a constant currency basis. The company reported adjusted EBITDA growth of 7% and highlighted key achievements including the acquisition of Endospan …

Medical equipment company to close St. Louis-area plant as it moves work to new $600M facility in NC

A global medical equipment company is planning to invest $600 million in a new manufacturing and distribution hub in North Carolina. This development will result in the closure of its existing St. Louis-area plant, with operations being consolidated into the new facility. The move …

UFP Technologies (UFPT) Stock Jumps As Record EPS Reshapes The Debate

BTIG raises Haemonetics stock price target to $96 on strong results

BTIG has increased its price target for Haemonetics Corp. (NYSE:HAE) to $96 from $84, maintaining a Buy rating after the company reported strong first-quarter revenues and adjusted earnings per share that surpassed consensus estimates. All segments performed well, with Interventional Technologies returning to growth …

iRhythm earnings up next: Narrowing losses in focus tonight

iRhythm Technologies Inc. is scheduled to report second-quarter earnings, with analysts expecting a narrower loss of 5 cents per share and revenue of $219.3 million, indicating substantial improvement from the previous quarter. Investors will be focused on the company's ability to maintain rapid growth …

electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates

electroCore, Inc. (ECOR) reported a Q2 loss of $0.33 per share, exceeding the Zacks Consensus Estimate of a $0.41 loss, and posted revenues of $9.45 million, surpassing estimates by 0.92%. The company's stock has gained 45.6% year-to-date, outperforming the S&P 500. Currently, electroCore holds …

MaxCyte | 4: Statement of changes in beneficial ownership of securities-Director Johnston John Joseph

This document is a statement of changes in beneficial ownership of securities for Director Johnston John Joseph at MaxCyte. These types of filings are routine disclosures required for company insiders. The specific details of the changes in ownership are contained within the document.

Neogen Corp (NASDAQ: NEOG) CEO notes son's indirect buy of 370 shares

Neogen Corp CEO Mikheal Nassif reported an indirect purchase of 370 shares of Common Stock at $11.81 per share on August 4, 2026. The shares are held by his son, bringing the reported indirect holdings to 1,074 shares, though Nassif disclaims beneficial ownership. This …

TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3

TD Cowen has reiterated its Buy rating on Pacific Biosciences of California (PACB.US) and maintained its target price at $3. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Artivion earnings on deck: Can FDA approval revive growth? By Investing.com

Artivion Inc. is set to report its second-quarter earnings, with investors focusing on whether its recent FDA premarket approval for the AMDS Hybrid Prosthesis can counteract slowing sales and revive growth. Despite a 46% drop in shares from their 52-week high and a sequential …

All eyes on Quidel earnings as estimates tumble, asset sale looms

Quidel Corporation is set to report its second-quarter earnings after market close on Thursday, August 6, 2026, with analysts anticipating a loss of 4 cents per share. Investor confidence has waned due to declining EPS estimates and uncertainty surrounding the potential $1.5 billion sale …

Standard BioTools Inc. (LAB) Stock Price, News, Quote & History

This article provides comprehensive financial information for Standard BioTools Inc. (LAB), including its current stock price, historical data, and analyst ratings. It details the company's overview, its segments in proteomics and genomics, key products like the SomaScan platform and CyTOF technology, and financial performance …